The Fibrate Drugs Global Market Report 2023, provides comprehensive information on the fibrate drugs market across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten year historic period – 2010-2021, and a ten year forecast period – 2023-2032.
Learn More On The Fibrate Drugs Market’s Growth:
https://www.thebusinessresearchcompany.com/report/fibrate-drugs-global-market-report
The global fibrate drugs market size is expected to grow from $3.17 billion in 2022 to $3.36 billion in 2023 at a compound annual growth rate (CAGR) of 6.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of fibrate drugs market is expected to reach $4.11 billion in 2027 at a CAGR of 5.2%.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample_request?id=11932&type=smp
Product innovations are a key trend gaining popularity in the fibrate drugs market. Major companies operating in the fibrate drugs market are focused on developing innovative solutions to sustain their position in the market. For instance, in November 2021, Lupin Limited, an India-based innovation-led transnational pharmaceutical company, launched an authorized generic version of Antara (Fenofibrate) Capsules, 30 mg, and 90 mg. In adult patients with primary hypercholesterolemia, fenofibrate capsules are recommended as an adjunctive therapy to diet to lower elevated levels of low-density lipoprotein cholesterol (LDL-C), total cholesterol (total-c), triglycerides (TG), and apolipoprotein B (Apo B), and to raise levels of high-density lipoprotein cholesterol (HDL-C).
The fibrate drugs market is segmented:
1) By Drug Type: Clofibrate, Fenofibrates, Fenofibric Acids, Gemfibrozil, Other Drugs
2) By Indication: Hypercholesterolemia, Heart Attacks, Other Indications
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
North America was the largest region in the fibrate drugs market in 2022.
The table of contents in TBRC’s fibrate drugs market report includes:
- Executive Summary
- Fibrate Drugs Market Characteristics
- Fibrate Drugs Market Trends And Strategies
- Fibrate Drugs Market – Macro Economic Scenario
- Fibrate Drugs Market Segmentation
.
.
.
- Global Fibrate Drugs Market Competitive Benchmarking
- Global Fibrate Drugs Market Competitive Dashboard
- Key Mergers And Acquisitions In The Fibrate Drugs Market
- Fibrate Drugs Market Future Outlook and Potential Analysis
- Appendix
Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries. Through the report businesses can gain a thorough understanding of the market’s size, growth rate, major drivers and leading players.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
